Combined magnetic resonance spectroscopy and dynamic contrast-enhanced imaging for prostate cancer detection

Abstract Background The use of magnetic resonance spectroscopy imaging (MRSI) and dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) have emerged as a valid diagnostic tools for prostate cancer (CaP). Methods Men with PSA levels below 10 ng/ml were enrolled in a prospective cohort study...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Urologic oncology 2013-08, Vol.31 (6), p.761-765
Hauptverfasser: Perdonà, Sisto, M.D, Di Lorenzo, Giuseppe, M.D., Ph.D, Autorino, Riccardo, M.D., Ph.D, Buonerba, Carlo, M.D, De Sio, Marco, Ph.D, Setola, Sergio Venanzio, M.D, Fusco, Roberta, M.D, Ronza, Francesco Michele, M.D, Caraglia, Michele, Ph.D, Ferro, Matteo, M.D, Petrillo, Antonella, M.D
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 765
container_issue 6
container_start_page 761
container_title Urologic oncology
container_volume 31
creator Perdonà, Sisto, M.D
Di Lorenzo, Giuseppe, M.D., Ph.D
Autorino, Riccardo, M.D., Ph.D
Buonerba, Carlo, M.D
De Sio, Marco, Ph.D
Setola, Sergio Venanzio, M.D
Fusco, Roberta, M.D
Ronza, Francesco Michele, M.D
Caraglia, Michele, Ph.D
Ferro, Matteo, M.D
Petrillo, Antonella, M.D
description Abstract Background The use of magnetic resonance spectroscopy imaging (MRSI) and dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) have emerged as a valid diagnostic tools for prostate cancer (CaP). Methods Men with PSA levels below 10 ng/ml were enrolled in a prospective cohort study and underwent combined MRSI and DCE-MRI and transrectal ultrasound-guided prostate biopsy. Imaging was performed using a 1.5 T MR scanner (Symphony TIM; Siemens, Erlangen, Germany) with an endorectal coil (Medrad; Pittsburg, PA), inflated with 60 cc of air. Three-dimensional magnetic resonance spectroscopic data were acquired by using water and a lipid-suppressed double-spin-echo point-resolved spectroscopy sequence, which was optimized for quantitative detection of both choline and citrate. Dynamic contrast-enhanced MRI sequences were obtained with 3D T1-weighted FLASH images before and during rapid bolus administration of intravenous paramagnetic contrast medium gadoteric acid. Specificity, sensitivity, positive predictive value, negative predictive value, and accuracy were computed considering patients, each of the 2 lobes, each of the 6 sextants, and each 12th part of the prostate gland as single measurements. Results Overall, 106 patients were included in the analysis. Median age was 65.9 years (range, 61.2–70.5 years) and median PSA level at study entry was 7.1 ng/ml (range, 2.5–9.9). CaP was detected at biopsy in 24 patients (22.6 % of the population) with a median Gleason score of 8 (range 4–10). Diagnostic accuracy of combined MRSI and DCE-MRI was 85%, sensitivity was 71%, and specificity was 48%, considering patients as single measurements, with a negative predictive value of 91%, but a positive predictive value of only 19%. Positive predictive value of the examination improved to 25% for patients who repeated biopsy. Conclusions Although this study confirms the potential usefulness of MRI for the diagnosis of CaP, the positive predictive value obtained was unacceptably low due to the high number of false positives recorded. Nevertheless, the high negative predictive value of the examination may serve to avoid unnecessary biopsies. Future research should be directed at assessing the value of combining MRI-based techniques with novel biochemical markers for the diagnosis of CaP in patients with low PSA levels.
doi_str_mv 10.1016/j.urolonc.2011.07.010
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1413166539</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1078143911002304</els_id><sourcerecordid>1413166539</sourcerecordid><originalsourceid>FETCH-LOGICAL-c420t-af9ac149a58840ecb71b96e98d9d28cc6e2d3dd269cc7da33a83e000abcf8ea83</originalsourceid><addsrcrecordid>eNqFkUGP1DAMhSsEYpeFnwDKkUuL3XbS5gJCI2BXWokDcI5Sx10ytMmQtEjz70k1AwcunJIo7z3bn4viJUKFgPLNoVpjmIKnqgbECroKEB4V19h3TVm3Sj7Od-j6EttGXRXPUjoAYNsjPi2ualQglZTXxbQP8-A8WzGbB8-LIxE5BW88sUhHpiWGROF4EsZbYU_ezFlCwS_RpKVk_31TWuGy3fkHMYYojtmymIUFbX9RWF5yjgv-efFkNFPiF5fzpvj28cPX_W15__nT3f79fUltDUtpRmUIW2V2fd8C09DhoCSr3ipb90SSa9tYW0tF1FnTNKZvGADMQGPP-XFTvD7n5k5-rpwWPbtEPE3Gc1iTxhYblHLXqCzdnaWUm06RR32MeZZ40gh6A60P-gJab6A1dDqDzr5XlxLrMLP96_pDNgvenQWcB_3lOOpEjjdWLmYa2gb33xJv_0mgyXlHZvrBJ06HsEafKWrUqdagv2zb3paNCFA30Da_AYT-qfg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1413166539</pqid></control><display><type>article</type><title>Combined magnetic resonance spectroscopy and dynamic contrast-enhanced imaging for prostate cancer detection</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Perdonà, Sisto, M.D ; Di Lorenzo, Giuseppe, M.D., Ph.D ; Autorino, Riccardo, M.D., Ph.D ; Buonerba, Carlo, M.D ; De Sio, Marco, Ph.D ; Setola, Sergio Venanzio, M.D ; Fusco, Roberta, M.D ; Ronza, Francesco Michele, M.D ; Caraglia, Michele, Ph.D ; Ferro, Matteo, M.D ; Petrillo, Antonella, M.D</creator><creatorcontrib>Perdonà, Sisto, M.D ; Di Lorenzo, Giuseppe, M.D., Ph.D ; Autorino, Riccardo, M.D., Ph.D ; Buonerba, Carlo, M.D ; De Sio, Marco, Ph.D ; Setola, Sergio Venanzio, M.D ; Fusco, Roberta, M.D ; Ronza, Francesco Michele, M.D ; Caraglia, Michele, Ph.D ; Ferro, Matteo, M.D ; Petrillo, Antonella, M.D</creatorcontrib><description>Abstract Background The use of magnetic resonance spectroscopy imaging (MRSI) and dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) have emerged as a valid diagnostic tools for prostate cancer (CaP). Methods Men with PSA levels below 10 ng/ml were enrolled in a prospective cohort study and underwent combined MRSI and DCE-MRI and transrectal ultrasound-guided prostate biopsy. Imaging was performed using a 1.5 T MR scanner (Symphony TIM; Siemens, Erlangen, Germany) with an endorectal coil (Medrad; Pittsburg, PA), inflated with 60 cc of air. Three-dimensional magnetic resonance spectroscopic data were acquired by using water and a lipid-suppressed double-spin-echo point-resolved spectroscopy sequence, which was optimized for quantitative detection of both choline and citrate. Dynamic contrast-enhanced MRI sequences were obtained with 3D T1-weighted FLASH images before and during rapid bolus administration of intravenous paramagnetic contrast medium gadoteric acid. Specificity, sensitivity, positive predictive value, negative predictive value, and accuracy were computed considering patients, each of the 2 lobes, each of the 6 sextants, and each 12th part of the prostate gland as single measurements. Results Overall, 106 patients were included in the analysis. Median age was 65.9 years (range, 61.2–70.5 years) and median PSA level at study entry was 7.1 ng/ml (range, 2.5–9.9). CaP was detected at biopsy in 24 patients (22.6 % of the population) with a median Gleason score of 8 (range 4–10). Diagnostic accuracy of combined MRSI and DCE-MRI was 85%, sensitivity was 71%, and specificity was 48%, considering patients as single measurements, with a negative predictive value of 91%, but a positive predictive value of only 19%. Positive predictive value of the examination improved to 25% for patients who repeated biopsy. Conclusions Although this study confirms the potential usefulness of MRI for the diagnosis of CaP, the positive predictive value obtained was unacceptably low due to the high number of false positives recorded. Nevertheless, the high negative predictive value of the examination may serve to avoid unnecessary biopsies. Future research should be directed at assessing the value of combining MRI-based techniques with novel biochemical markers for the diagnosis of CaP in patients with low PSA levels.</description><identifier>ISSN: 1078-1439</identifier><identifier>EISSN: 1873-2496</identifier><identifier>DOI: 10.1016/j.urolonc.2011.07.010</identifier><identifier>PMID: 21906966</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Aged ; Biopsy ; Cohort Studies ; Contrast Media - pharmacology ; Humans ; Imaging, Three-Dimensional ; Magnetic resonance ; Magnetic Resonance Imaging - methods ; Magnetic Resonance Spectroscopy - methods ; Male ; Meglumine - pharmacology ; Middle Aged ; Multimodal Imaging ; Neoplasm Grading ; Organometallic Compounds - pharmacology ; Predictive Value of Tests ; Prospective Studies ; Prostate cancer ; Prostate-Specific Antigen - blood ; Prostatic Neoplasms - diagnosis ; Prostatic Neoplasms - pathology ; Reproducibility of Results ; Sensitivity and Specificity ; Spectroscopy ; Urology</subject><ispartof>Urologic oncology, 2013-08, Vol.31 (6), p.761-765</ispartof><rights>Elsevier Inc.</rights><rights>2013 Elsevier Inc.</rights><rights>Copyright © 2013 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c420t-af9ac149a58840ecb71b96e98d9d28cc6e2d3dd269cc7da33a83e000abcf8ea83</citedby><cites>FETCH-LOGICAL-c420t-af9ac149a58840ecb71b96e98d9d28cc6e2d3dd269cc7da33a83e000abcf8ea83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.urolonc.2011.07.010$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3541,27915,27916,45986</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21906966$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Perdonà, Sisto, M.D</creatorcontrib><creatorcontrib>Di Lorenzo, Giuseppe, M.D., Ph.D</creatorcontrib><creatorcontrib>Autorino, Riccardo, M.D., Ph.D</creatorcontrib><creatorcontrib>Buonerba, Carlo, M.D</creatorcontrib><creatorcontrib>De Sio, Marco, Ph.D</creatorcontrib><creatorcontrib>Setola, Sergio Venanzio, M.D</creatorcontrib><creatorcontrib>Fusco, Roberta, M.D</creatorcontrib><creatorcontrib>Ronza, Francesco Michele, M.D</creatorcontrib><creatorcontrib>Caraglia, Michele, Ph.D</creatorcontrib><creatorcontrib>Ferro, Matteo, M.D</creatorcontrib><creatorcontrib>Petrillo, Antonella, M.D</creatorcontrib><title>Combined magnetic resonance spectroscopy and dynamic contrast-enhanced imaging for prostate cancer detection</title><title>Urologic oncology</title><addtitle>Urol Oncol</addtitle><description>Abstract Background The use of magnetic resonance spectroscopy imaging (MRSI) and dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) have emerged as a valid diagnostic tools for prostate cancer (CaP). Methods Men with PSA levels below 10 ng/ml were enrolled in a prospective cohort study and underwent combined MRSI and DCE-MRI and transrectal ultrasound-guided prostate biopsy. Imaging was performed using a 1.5 T MR scanner (Symphony TIM; Siemens, Erlangen, Germany) with an endorectal coil (Medrad; Pittsburg, PA), inflated with 60 cc of air. Three-dimensional magnetic resonance spectroscopic data were acquired by using water and a lipid-suppressed double-spin-echo point-resolved spectroscopy sequence, which was optimized for quantitative detection of both choline and citrate. Dynamic contrast-enhanced MRI sequences were obtained with 3D T1-weighted FLASH images before and during rapid bolus administration of intravenous paramagnetic contrast medium gadoteric acid. Specificity, sensitivity, positive predictive value, negative predictive value, and accuracy were computed considering patients, each of the 2 lobes, each of the 6 sextants, and each 12th part of the prostate gland as single measurements. Results Overall, 106 patients were included in the analysis. Median age was 65.9 years (range, 61.2–70.5 years) and median PSA level at study entry was 7.1 ng/ml (range, 2.5–9.9). CaP was detected at biopsy in 24 patients (22.6 % of the population) with a median Gleason score of 8 (range 4–10). Diagnostic accuracy of combined MRSI and DCE-MRI was 85%, sensitivity was 71%, and specificity was 48%, considering patients as single measurements, with a negative predictive value of 91%, but a positive predictive value of only 19%. Positive predictive value of the examination improved to 25% for patients who repeated biopsy. Conclusions Although this study confirms the potential usefulness of MRI for the diagnosis of CaP, the positive predictive value obtained was unacceptably low due to the high number of false positives recorded. Nevertheless, the high negative predictive value of the examination may serve to avoid unnecessary biopsies. Future research should be directed at assessing the value of combining MRI-based techniques with novel biochemical markers for the diagnosis of CaP in patients with low PSA levels.</description><subject>Aged</subject><subject>Biopsy</subject><subject>Cohort Studies</subject><subject>Contrast Media - pharmacology</subject><subject>Humans</subject><subject>Imaging, Three-Dimensional</subject><subject>Magnetic resonance</subject><subject>Magnetic Resonance Imaging - methods</subject><subject>Magnetic Resonance Spectroscopy - methods</subject><subject>Male</subject><subject>Meglumine - pharmacology</subject><subject>Middle Aged</subject><subject>Multimodal Imaging</subject><subject>Neoplasm Grading</subject><subject>Organometallic Compounds - pharmacology</subject><subject>Predictive Value of Tests</subject><subject>Prospective Studies</subject><subject>Prostate cancer</subject><subject>Prostate-Specific Antigen - blood</subject><subject>Prostatic Neoplasms - diagnosis</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Reproducibility of Results</subject><subject>Sensitivity and Specificity</subject><subject>Spectroscopy</subject><subject>Urology</subject><issn>1078-1439</issn><issn>1873-2496</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkUGP1DAMhSsEYpeFnwDKkUuL3XbS5gJCI2BXWokDcI5Sx10ytMmQtEjz70k1AwcunJIo7z3bn4viJUKFgPLNoVpjmIKnqgbECroKEB4V19h3TVm3Sj7Od-j6EttGXRXPUjoAYNsjPi2ualQglZTXxbQP8-A8WzGbB8-LIxE5BW88sUhHpiWGROF4EsZbYU_ezFlCwS_RpKVk_31TWuGy3fkHMYYojtmymIUFbX9RWF5yjgv-efFkNFPiF5fzpvj28cPX_W15__nT3f79fUltDUtpRmUIW2V2fd8C09DhoCSr3ipb90SSa9tYW0tF1FnTNKZvGADMQGPP-XFTvD7n5k5-rpwWPbtEPE3Gc1iTxhYblHLXqCzdnaWUm06RR32MeZZ40gh6A60P-gJab6A1dDqDzr5XlxLrMLP96_pDNgvenQWcB_3lOOpEjjdWLmYa2gb33xJv_0mgyXlHZvrBJ06HsEafKWrUqdagv2zb3paNCFA30Da_AYT-qfg</recordid><startdate>20130801</startdate><enddate>20130801</enddate><creator>Perdonà, Sisto, M.D</creator><creator>Di Lorenzo, Giuseppe, M.D., Ph.D</creator><creator>Autorino, Riccardo, M.D., Ph.D</creator><creator>Buonerba, Carlo, M.D</creator><creator>De Sio, Marco, Ph.D</creator><creator>Setola, Sergio Venanzio, M.D</creator><creator>Fusco, Roberta, M.D</creator><creator>Ronza, Francesco Michele, M.D</creator><creator>Caraglia, Michele, Ph.D</creator><creator>Ferro, Matteo, M.D</creator><creator>Petrillo, Antonella, M.D</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20130801</creationdate><title>Combined magnetic resonance spectroscopy and dynamic contrast-enhanced imaging for prostate cancer detection</title><author>Perdonà, Sisto, M.D ; Di Lorenzo, Giuseppe, M.D., Ph.D ; Autorino, Riccardo, M.D., Ph.D ; Buonerba, Carlo, M.D ; De Sio, Marco, Ph.D ; Setola, Sergio Venanzio, M.D ; Fusco, Roberta, M.D ; Ronza, Francesco Michele, M.D ; Caraglia, Michele, Ph.D ; Ferro, Matteo, M.D ; Petrillo, Antonella, M.D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c420t-af9ac149a58840ecb71b96e98d9d28cc6e2d3dd269cc7da33a83e000abcf8ea83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Aged</topic><topic>Biopsy</topic><topic>Cohort Studies</topic><topic>Contrast Media - pharmacology</topic><topic>Humans</topic><topic>Imaging, Three-Dimensional</topic><topic>Magnetic resonance</topic><topic>Magnetic Resonance Imaging - methods</topic><topic>Magnetic Resonance Spectroscopy - methods</topic><topic>Male</topic><topic>Meglumine - pharmacology</topic><topic>Middle Aged</topic><topic>Multimodal Imaging</topic><topic>Neoplasm Grading</topic><topic>Organometallic Compounds - pharmacology</topic><topic>Predictive Value of Tests</topic><topic>Prospective Studies</topic><topic>Prostate cancer</topic><topic>Prostate-Specific Antigen - blood</topic><topic>Prostatic Neoplasms - diagnosis</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Reproducibility of Results</topic><topic>Sensitivity and Specificity</topic><topic>Spectroscopy</topic><topic>Urology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Perdonà, Sisto, M.D</creatorcontrib><creatorcontrib>Di Lorenzo, Giuseppe, M.D., Ph.D</creatorcontrib><creatorcontrib>Autorino, Riccardo, M.D., Ph.D</creatorcontrib><creatorcontrib>Buonerba, Carlo, M.D</creatorcontrib><creatorcontrib>De Sio, Marco, Ph.D</creatorcontrib><creatorcontrib>Setola, Sergio Venanzio, M.D</creatorcontrib><creatorcontrib>Fusco, Roberta, M.D</creatorcontrib><creatorcontrib>Ronza, Francesco Michele, M.D</creatorcontrib><creatorcontrib>Caraglia, Michele, Ph.D</creatorcontrib><creatorcontrib>Ferro, Matteo, M.D</creatorcontrib><creatorcontrib>Petrillo, Antonella, M.D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Urologic oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Perdonà, Sisto, M.D</au><au>Di Lorenzo, Giuseppe, M.D., Ph.D</au><au>Autorino, Riccardo, M.D., Ph.D</au><au>Buonerba, Carlo, M.D</au><au>De Sio, Marco, Ph.D</au><au>Setola, Sergio Venanzio, M.D</au><au>Fusco, Roberta, M.D</au><au>Ronza, Francesco Michele, M.D</au><au>Caraglia, Michele, Ph.D</au><au>Ferro, Matteo, M.D</au><au>Petrillo, Antonella, M.D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Combined magnetic resonance spectroscopy and dynamic contrast-enhanced imaging for prostate cancer detection</atitle><jtitle>Urologic oncology</jtitle><addtitle>Urol Oncol</addtitle><date>2013-08-01</date><risdate>2013</risdate><volume>31</volume><issue>6</issue><spage>761</spage><epage>765</epage><pages>761-765</pages><issn>1078-1439</issn><eissn>1873-2496</eissn><abstract>Abstract Background The use of magnetic resonance spectroscopy imaging (MRSI) and dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) have emerged as a valid diagnostic tools for prostate cancer (CaP). Methods Men with PSA levels below 10 ng/ml were enrolled in a prospective cohort study and underwent combined MRSI and DCE-MRI and transrectal ultrasound-guided prostate biopsy. Imaging was performed using a 1.5 T MR scanner (Symphony TIM; Siemens, Erlangen, Germany) with an endorectal coil (Medrad; Pittsburg, PA), inflated with 60 cc of air. Three-dimensional magnetic resonance spectroscopic data were acquired by using water and a lipid-suppressed double-spin-echo point-resolved spectroscopy sequence, which was optimized for quantitative detection of both choline and citrate. Dynamic contrast-enhanced MRI sequences were obtained with 3D T1-weighted FLASH images before and during rapid bolus administration of intravenous paramagnetic contrast medium gadoteric acid. Specificity, sensitivity, positive predictive value, negative predictive value, and accuracy were computed considering patients, each of the 2 lobes, each of the 6 sextants, and each 12th part of the prostate gland as single measurements. Results Overall, 106 patients were included in the analysis. Median age was 65.9 years (range, 61.2–70.5 years) and median PSA level at study entry was 7.1 ng/ml (range, 2.5–9.9). CaP was detected at biopsy in 24 patients (22.6 % of the population) with a median Gleason score of 8 (range 4–10). Diagnostic accuracy of combined MRSI and DCE-MRI was 85%, sensitivity was 71%, and specificity was 48%, considering patients as single measurements, with a negative predictive value of 91%, but a positive predictive value of only 19%. Positive predictive value of the examination improved to 25% for patients who repeated biopsy. Conclusions Although this study confirms the potential usefulness of MRI for the diagnosis of CaP, the positive predictive value obtained was unacceptably low due to the high number of false positives recorded. Nevertheless, the high negative predictive value of the examination may serve to avoid unnecessary biopsies. Future research should be directed at assessing the value of combining MRI-based techniques with novel biochemical markers for the diagnosis of CaP in patients with low PSA levels.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>21906966</pmid><doi>10.1016/j.urolonc.2011.07.010</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1078-1439
ispartof Urologic oncology, 2013-08, Vol.31 (6), p.761-765
issn 1078-1439
1873-2496
language eng
recordid cdi_proquest_miscellaneous_1413166539
source MEDLINE; ScienceDirect Journals (5 years ago - present)
subjects Aged
Biopsy
Cohort Studies
Contrast Media - pharmacology
Humans
Imaging, Three-Dimensional
Magnetic resonance
Magnetic Resonance Imaging - methods
Magnetic Resonance Spectroscopy - methods
Male
Meglumine - pharmacology
Middle Aged
Multimodal Imaging
Neoplasm Grading
Organometallic Compounds - pharmacology
Predictive Value of Tests
Prospective Studies
Prostate cancer
Prostate-Specific Antigen - blood
Prostatic Neoplasms - diagnosis
Prostatic Neoplasms - pathology
Reproducibility of Results
Sensitivity and Specificity
Spectroscopy
Urology
title Combined magnetic resonance spectroscopy and dynamic contrast-enhanced imaging for prostate cancer detection
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T03%3A39%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Combined%20magnetic%20resonance%20spectroscopy%20and%20dynamic%20contrast-enhanced%20imaging%20for%20prostate%20cancer%20detection&rft.jtitle=Urologic%20oncology&rft.au=Perdon%C3%A0,%20Sisto,%20M.D&rft.date=2013-08-01&rft.volume=31&rft.issue=6&rft.spage=761&rft.epage=765&rft.pages=761-765&rft.issn=1078-1439&rft.eissn=1873-2496&rft_id=info:doi/10.1016/j.urolonc.2011.07.010&rft_dat=%3Cproquest_cross%3E1413166539%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1413166539&rft_id=info:pmid/21906966&rft_els_id=1_s2_0_S1078143911002304&rfr_iscdi=true